MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outpatient and home settings; MindMotion Companion, an application that manages prescription, monitoring and documentation across MindMaze Therapeutics' neurotherapeutics ecosystem; and the patient app, a patient-facing mobile application, that supports clinic-to-home continuity by making prescribed therapy easy to follow outside the clinic. It also provides Izar hand therapy device which supports fine motor rehabilitation; Physilog sensor, a wearable inertial sensing device designed to quantify human movement; toaprun, a training for Parkinson's therapy-reimagined through play. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
What is MindMaze Therapeutics SA stock price today?▼
The current price of V6M0.MU is €0.32 EUR — it has increased by +0% in the past 24 hours. Watch MindMaze Therapeutics SA stock price performance more closely on the chart.
What is MindMaze Therapeutics SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange MindMaze Therapeutics SA stocks are traded under the ticker V6M0.MU.
How many employees does MindMaze Therapeutics SA have?▼
As of July 10, 2026, the company has 10 employees.
In which sector is MindMaze Therapeutics SA located?▼
MindMaze Therapeutics SA operates in the Other sector.
When did MindMaze Therapeutics SA complete a stock split?▼
The last stock split for MindMaze Therapeutics SA was on May 05, 2023 with a ratio of 1:2.
Where is MindMaze Therapeutics SA headquartered?▼
MindMaze Therapeutics SA is headquartered in Geneva, Switzerland.